Over the past 5 years, recombinant antibodies have been established at a growing rate into clinical practice for the treatment of diseases ranging from cancer to autoimmune and infectious diseases. The Office of the Vice Provost for Research, in conjunction with CTTC and VICB, has partnered with Deerfield to bring together experts in discovery and development of antibody therapeutics to discuss and review the state of the art in the field. This event aims to expose faculty and staff to therapeutic antibody discovery in an academic setting and foster interest in submission of innovative ideas for antibody targets through an upcoming RFP for Ancora, the collaboration between Vanderbilt and Deerfield. For participants, the event will be an opportunity to gain insight into various aspects of therapeutic antibodies, including how to accelerate antibody discovery through proof-of-concept, and to better understand and leverage resources available on campus and through Ancora.
Therapeutic Antibody Discovery and Development
2:30-2:35 Welcome and Introductions
Moderator: Rob Carnahan PhD, Associate Professor of Pediatrics
2:35-3:20 Therapeutic Antibody Discovery and Development in the Academic Setting
Speaker: Ivo Lorenz, PhD, Vice President Antibody Discovery, Tri-Institutional Therapeutic Discovery Institute, and Biochemistry faculty at Weill Cornell Medicine
3:20-4:00 Current and Future Trends - Antibody Development
Larry Green, Ph.D, CEO Ablexis
Doug Johnson MD, Assistant Professor of Medicine
Ivo Lorenz Ph.D, VP Tri-Institutional Therapeutic Discovery Institute
Jens Meiler Ph.D, Professor of Chemistry
Rob Carnahan, Associate Professor of Pediatrics
4 -5:00 pm Reception, Light Hall lobby
External Speaker Bio:
Ivo Lorenz, PhD
Ivo is the head of the Antibody Discovery Laboratory at TDI, and a faculty member in the Biochemistry department of Weill Cornell Medicine. A native of Switzerland, Ivo obtained his PhD in Biochemistry from the Swiss Federal Institute of Technology in Zürich. After his postdoctoral training at The Rockefeller University, Ivo joined the International AIDS Vaccine Initiative, where he focused on novel immunogen design approaches to develop a prophylactic HIV vaccine. Prior to TDI, Ivo worked at Boehringer Ingelheim Pharmaceuticals, where he gained extensive experience in antibody drug discovery and project management for targets from various disease areas.
Larry Green, PhD
Larry is CEO and founder of Ablexis, and co-inventor of the AlivaMab Mouse. He also serves as CEO of AlivaMab Discovery Services. Larry has over a quarter century of experience in designing, creating and using transgenic mouse platforms for antibody drug discovery. Larry joined Aliva Biopharmaceuticals, Inc. in 2008 as CEO, where he optimized the blueprint for AlivaMab Mouse and procured a Series A financing, resulting in the founding of Ablexis, LLC in 2009. Prior to joining Aliva, he was a co-inventor of the XenoMouse® technology at Cell Genesys and was a scientific founder of the spin-out of Abgenix, where he served as designer and team leader for making improved versions of the XenoMouse® technology, director of antibody discovery operations, leader of the collaborations group, and the senior research representative on joint steering committees in alliances with Amgen, AstraZeneca, Pfizer amongst other companies.
Larry is an inventor on several dozen patents covering immunoglobulin transgenic mice and therapeutic antibodies. He received his Ph.D. in Molecular and Cellular Biology from the University of Wisconsin-Madison and did postdoctoral research at the University of Colorado at Boulder and Stanford University.